Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

General (Details Narrative)

v3.20.1
General (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Jun. 15, 2020
Feb. 27, 2019
Dec. 31, 2017
Accumulated losses $ (17,507,868) $ (5,693,353)      
Working capital 1,535,491        
Shareholders' deficit (6,248,812) (1,215,934)     $ (1,339,633)
Cash and cash equivalents 12,155 63,550      
Convertible Bridge Loans Transactions [Member]          
Proceeds from issuance of financial instruments 1,374,470 27,000      
Exercise of Stock Warrants into Shares [Member]          
Proceeds from issuance of financial instruments   324,258      
Private Placement Transactions [Member]          
Proceeds from issuance of financial instruments $ 295,000 $ 100,000      
Subsequent Event [Member]          
Cash and cash equivalents     $ 300,000    
Joint Venture Agreement [Member] | Breakthrough Diagnostics, Inc. [Member]          
Ownership percentage       19.99%